DE69429895T2 - Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten - Google Patents

Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten

Info

Publication number
DE69429895T2
DE69429895T2 DE69429895T DE69429895T DE69429895T2 DE 69429895 T2 DE69429895 T2 DE 69429895T2 DE 69429895 T DE69429895 T DE 69429895T DE 69429895 T DE69429895 T DE 69429895T DE 69429895 T2 DE69429895 T2 DE 69429895T2
Authority
DE
Germany
Prior art keywords
alkyl
hydrogen
disorder
syndrome
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429895T
Other languages
English (en)
Other versions
DE69429895D1 (de
Inventor
Richard Leslie Rudolph
Albert Thomas Derivan
Eric Anthony Muth
Gertrude Virginia Upton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69429895(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of DE69429895D1 publication Critical patent/DE69429895D1/de
Application granted granted Critical
Publication of DE69429895T2 publication Critical patent/DE69429895T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69429895T 1993-06-28 1994-06-13 Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten Expired - Lifetime DE69429895T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8384893A 1993-06-28 1993-06-28

Publications (2)

Publication Number Publication Date
DE69429895D1 DE69429895D1 (de) 2002-03-28
DE69429895T2 true DE69429895T2 (de) 2002-08-29

Family

ID=22181084

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69434872T Expired - Lifetime DE69434872T2 (de) 1993-06-28 1994-06-13 Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
DE69435095T Revoked DE69435095T2 (de) 1993-06-28 1994-06-13 Neue Behandlungsmethoden durch Verwendung von Phenethylaminderivaten
DE69429895T Expired - Lifetime DE69429895T2 (de) 1993-06-28 1994-06-13 Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69434872T Expired - Lifetime DE69434872T2 (de) 1993-06-28 1994-06-13 Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
DE69435095T Revoked DE69435095T2 (de) 1993-06-28 1994-06-13 Neue Behandlungsmethoden durch Verwendung von Phenethylaminderivaten

Country Status (15)

Country Link
US (8) US5916923A (de)
EP (3) EP1738753B1 (de)
JP (2) JPH0789851A (de)
KR (1) KR100342762B1 (de)
AT (3) ATE392893T1 (de)
AU (2) AU6592994A (de)
CA (1) CA2126305C (de)
CY (1) CY2315B1 (de)
DE (3) DE69434872T2 (de)
DK (3) DK1153603T3 (de)
ES (3) ES2174864T3 (de)
HK (1) HK1038880B (de)
LV (1) LV12881B (de)
PT (3) PT1738753E (de)
SG (1) SG47711A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP0667150B1 (de) * 1994-02-14 2002-12-11 Wyeth Venlafaxin und seine Analoga zum Herbeiführen einer Verbesserung der kognitiven Funktionen
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (de) * 1996-03-25 2015-08-26 Wyeth LLC Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
JP2002520353A (ja) * 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
CZ20013607A3 (cs) * 1999-04-06 2002-06-12 Sepracor Inc. Farmaceutický prostředek
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
WO2001049679A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4220243B2 (ja) * 2001-02-12 2009-02-04 ワイス Ｏ−デスメチル−ベンラファキシンの新規コハク酸塩
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
CA2467593A1 (en) * 2001-12-05 2003-06-19 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
AR039164A1 (es) 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
AU2003226748A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Compositions of venlafaxine base
AR039163A1 (es) 2002-03-28 2005-02-09 Synthon Bv Besilato de venlafaxina
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
PL377473A1 (pl) * 2002-11-28 2006-02-06 Themis Laboratories Private Limited Sposób produkcji mikropeletek o przedłużonym uwalnianiu zawierających chlorowodorek wenlafaksyny
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004075902A1 (en) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
CA2604916A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AR056979A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofuranos y usos de los mismos
WO2006116149A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
JP2008538581A (ja) * 2005-04-22 2008-10-30 ワイス ｛［（２ｒ）−７−（２，６−ジクロロフェニル）−５−フルオロ−２，３−ジヒドロ−１−ベンゾフラン−２−イル］メチル｝アミン塩酸塩の結晶形態
WO2007047972A2 (en) * 2005-10-19 2007-04-26 Teva Pharmaceutical Industries Ltd. Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride
SI1954669T1 (sl) * 2005-12-01 2016-01-29 Auspex Pharmaceuticals, Inc. Substituirani fenetilamini s serotoninergično in / ali noradrenalinsko aktivnostjo
AU2006322057A1 (en) 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
BRPI0709159A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp combinações terapêuticas para o tratamento de depressão
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
JP2010507667A (ja) * 2006-10-25 2010-03-11 ワイス エルエルシー Ｏ−デスメチルベンラファキシンの単離されたヒドロキシおよびｎ−オキシド代謝産物および誘導体および治療方法
DK2125698T3 (en) * 2007-03-15 2016-11-07 Auspex Pharmaceuticals Inc Deuterated d9-VENLAFAXINE
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
EP2222302A1 (de) * 2007-11-20 2010-09-01 NeuroSearch A/S Verfahren zur behandlung von over-eating-störungen
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
CZ200969A3 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
US9223364B2 (en) * 2012-10-25 2015-12-29 Inhon International Co., Ltd. Heat dissipation control system for portable electrical device and control method thereof
KR102132304B1 (ko) 2020-02-17 2020-07-09 박광순 접이식 유아용 비데
RU2741226C1 (ru) * 2020-09-08 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики агрессии лиц с интернет-зависимостью

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) * 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US3894051A (en) * 1973-07-05 1975-07-08 Colgate Palmolive Co N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
EP0386117B1 (de) * 1987-10-22 1999-01-07 Massachusetts Institute Of Technology Behandlung des prämenstruellen oder späten lutealsphase-syndroms
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
FI910897A (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
ZA912277B (en) * 1990-03-29 1992-11-25 Lilly Co Eli The selective occupation of serotonin ic receptors
EP1208838A3 (de) * 1991-11-15 2003-07-09 Sepracor Inc. Reines S(+)Fluoxetin Isomer
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives

Also Published As

Publication number Publication date
US20010012855A1 (en) 2001-08-09
US20080176950A1 (en) 2008-07-24
AU5831298A (en) 1998-05-21
US6310101B1 (en) 2001-10-30
EP0639374A3 (de) 1995-08-02
US5916923A (en) 1999-06-29
US20020052405A1 (en) 2002-05-02
AU6592994A (en) 1995-01-05
DE69435095D1 (de) 2008-06-05
ES2174864T3 (es) 2002-11-16
ATE392893T1 (de) 2008-05-15
US6465524B2 (en) 2002-10-15
DK0639374T3 (da) 2002-05-06
HK1038880B (zh) 2006-12-22
EP1738753A3 (de) 2007-01-31
DE69429895D1 (de) 2002-03-28
DK1738753T3 (da) 2008-08-11
ATE213407T1 (de) 2002-03-15
EP0639374A2 (de) 1995-02-22
DK1153603T3 (da) 2006-12-18
US20030181517A1 (en) 2003-09-25
CA2126305A1 (en) 1994-12-29
EP1153603A3 (de) 2003-05-21
PT1153603E (pt) 2007-01-31
KR950000139A (ko) 1995-01-03
CA2126305C (en) 2006-10-17
PT1738753E (pt) 2008-06-19
HK1038880A1 (en) 2002-04-04
EP0639374B1 (de) 2002-02-20
EP1153603A2 (de) 2001-11-14
KR100342762B1 (ko) 2002-11-18
CY2315B1 (en) 2003-11-14
DE69434872D1 (de) 2006-11-30
US6555586B2 (en) 2003-04-29
DE69434872T2 (de) 2007-04-05
ES2273764T3 (es) 2007-05-16
LV12881B (en) 2002-11-20
EP1153603B1 (de) 2006-10-18
JP2006117689A (ja) 2006-05-11
PT639374E (pt) 2002-07-31
US20010053799A1 (en) 2001-12-20
US6444708B2 (en) 2002-09-03
JPH0789851A (ja) 1995-04-04
SG47711A1 (en) 1998-04-17
EP1738753B1 (de) 2008-04-23
EP1738753A2 (de) 2007-01-03
US20040110829A1 (en) 2004-06-10
DE69435095T2 (de) 2009-07-02
US6730706B2 (en) 2004-05-04
ATE342715T1 (de) 2006-11-15
ES2304041T3 (es) 2008-09-01

Similar Documents

Publication Publication Date Title
DE69429895T2 (de) Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
NO942415L (no) Fremgangsmåte for fremstilling av behandling av surgass og hydrokarbonvæskeströmmer
DK0582790T3 (da) Ny fremgangsmåde til fremstilling af 7-substituerede-9-[(substitueret glycyl)-amino]-6-demethyl-6-deoxytetracycliner
DE69133455D1 (de) Zwischenprodukte zur Herstellung von Camptothecin und Analogen
AR001074A1 (es) Composición para tratar amenorrea hipotalamica en un mamifero hembra no deprimido
SG165991A1 (en) Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives
ES2037779T3 (es) Procedimiento para preparar nuevos compuestos de amida.
HU9601217D0 (en) Antracyclinone derivatives and their use for treating amyloidosis
NO870423D0 (no) 5-substituert octahydroindolizin-analgetika-forbindelser og 7-keto-mellomprodukt.
FI860074A0 (fi) Oktahydroindolizinfoereningar anvaendbara som smaertstillande medel.
DK0667150T3 (da) Venlafaxin og dens analoger til fremkaldelse af en forbedring af de kognitive funktioner
DE59907469D1 (de) Ungesättigte oligophenolcyanate

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: WYETH (N.D.GES.D. STAATES DELAWARE), MADISON, N.J.

8364 No opposition during term of opposition